Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2805 - Chemotherapy-induced thrombocytopenia (CIT) in metastatic colorectal cancer (mCRC) patients

Date

09 Sep 2017

Session

Poster display session

Presenters

Karynsa Cetin

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

K. Cetin1, A. Toler2, M. Eisen3, G.A. Soff4

Author affiliations

  • 1 Center For Observational Research, AMGEN (Headquarters) - USA, 91320-1799 - Thousand Oaks/US
  • 2 Center For Observational Research, ICON/Docs Global, Inc. and AMGEN (Headquarters) - USA, 91320-1799 - Thousand Oaks/US
  • 3 Global Development, AMGEN (Headquarters) - USA, 91320-1799 - Thousand Oaks/US
  • 4 Hematology Service, Memorial Sloan-Kettering Cancer Center, 10065 - New York City/US
More

Resources

Abstract 2805

Background

Thrombocytopenia is a common hematologic toxicity of myelosuppressive chemotherapy and can complicate a patient’s care.

Methods

This is a descriptive secondary analysis of data from two large clinical trials of mCRC patients – 1,078 treatment-naïve patients receiving fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) and 1,067 previously-treated patients receiving fluorouracil, leucovorin, and irinotecan (FOLFIRI) – to investigate the frequency and clinical consequences of CIT. Evidence of CIT was studied in two ways: 1) recorded platelet counts throughout the study (overall and by grade:

Results

Evidence of CIT based solely on platelet count was relatively common in the FOLFOX4 study (37% of patients had ≥1 platelet count

Conclusions

In mCRC patients receiving chemotherapy, thrombocytopenia can pose a real clinical problem, commonly leading to chemotherapy delays and/or dose reductions and in some cases, necessitating platelet transfusion and cessation of chemotherapy treatment.

Clinical trial identification

This was a secondary analysis of data from two clinical trials: NCT00364013 and NCT00339183

Legal entity responsible for the study

Amgen Inc

Funding

Amgen Inc

Disclosure

K. Cetin: Employee of Amgen Inc and ownership of Amgen Inc stock. A. Toler: Employed by Amgen Inc M. Eisen: Employee of Amgen Inc and ownership of Amgen Inc stock. G.A. Soff: Research support from Amgen Inc. Consulting fees from Amgen Inc. Research funding from Janssen Pharmaceuticals.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.